Accent Therapeutics Bolsters Leadership Team with Key Executive Hires
LEXINGTON, Mass., Sept. 21, 2023 /PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the appointments of Jason Sager, M.D., as Chief Medical Officer, Steven Mennen, Ph.D., as Vice President of Pre-Clinical Development and Stuart Ince, Ph.D. as Vice President of Program Leadership.
- "Our dedication to fortifying our team underscores the remarkable progress we've achieved as Accent advances its lead programs towards the clinic," said Shakti Narayan, Chief Executive Officer of Accent.
- Together, Jason, Steven, and Stuart's combined experience will be immensely valuable as Accent moves towards becoming a clinical-stage company and bringing novel therapies to patients."
- These key executive hires enhance Accent's positioning to potentially advance two investigational programs into the clinic.
- Accent is also on track to begin IND-enabling studies for a second undisclosed program by the end of 2023.